PTOISB/08x (08-03)
Approved for use through 07/31/2006 (108 068-03)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to resp Application Number

			Filing Date								
INFORMATION DISCLOSURE				First Named Inventor		KIM,	l, Kab-Sig				
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)			Art Unit								
			Examiner Na	Examiner Name							
				Attorney Docket Number 5656BIO-1							
U.S.PATENTS Remove											
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant Relev			Releva	es,Columns,Lines where evant Passages or Relevant ures Appear		
	1	6264933		2001-07-24	Bodelin, S	Sophie	et al.				
If you wish to add additional U.S. Patent citation information please click the Add button.											
U.S.PATENT APPLICATION PUBLICATIONS Remove											
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	of sited Decument Rele		Releva	es,Columns,Lines where want Passages or Relevant res Appear			
	1										
If you wish to add additional U.S. Published Application citation information please click the Add button. Add											
FOREIGN PATENT DOCUMENTS Remove											
						-T		Te	anns Co	lumns Lines	

	FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code4	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T5	
	1	11-255602	JP		1999-09-21	Nipponsoda Co. Ltd.			
	2	7-184556	JP		1995-07-25	Takeda Shokuhin Kogyo KK, Sanki Shoji KK			
	3	3-30603	JP		1991-02-08	Asanohiroyoshi			

Application Number | Filing Date | First Named Inventor | Kill, Kab-Sig | Art Unit | Examiner Name | Attorney Doctet Number | Fisch State | First Named Inventor | Kill, Kab-Sig | Art Unit | Examiner Name | Attorney Doctet Number | 5565810-1

If you wis	h to a	additional Foreign Patent Document citation information please click the Add button Add		
		NON-PATENT LITERATURE DOCUMENTS Remove		
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Initials* No No publisher, city and/or country where published.				
	1	nternational Search Report for PCT Application No. PCT/KR2004/002914		
If you wis	h to a	additional non-patent literature document citation information please click the Add button Add		
		EXAMINER SIGNATURE		
Examiner	Signa	re Date Considered		
*EXAMIN	ER: In	al if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a		

1 See Knd Codeor of USPTO Patent Documents at yeary_USPTO_GOD(or NPEP 901.64. ² Either office that issued the document, by the hordcoments, by mandator ST3. ³ For Apparence patent documents, by mandator of the year of the Empore or must preced the Series and number of the Patent document. ⁴ Knild of documents by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language transition is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number Fing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number Fing Date Fing Date Fing Date Fing Date Fing Manage Inventor KIM, Kab-Sig Art Unit Examiner Number Indicated Inventor Indicated Inventor Indicated Indicate

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eV1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Gary J. Connell/	Date (YYYY-MM-DD)	
Name/Print	Gary J. Connell	Registration Number	32020

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S.231.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.